Stocks in Japan struggled to advance amid the weakness in tech stocks following the U.S. Federal Reserve's hawkish comments and rate decisions. Sumitomo Pharma suspended its dividend and raised its estimate of losses in fiscal 2024.
If you want to see the full data, please log in to your account. Logging in gives you complete access to all available information, features, and detailed insights that are not visible to guest users.
